U.S. President Donald Trump has announced a new round of tariffs targeting certain branded pharmaceutical imports. The move comes one year after the administration introduced sweeping global tariffs that were later struck down by the U.S. Supreme Court in February.
The latest measures aim to restore tariff revenues lost after the court ruling and strengthen domestic manufacturing. However, several business groups have criticized the decision, warning that the tariffs could increase costs for companies and consumers, particularly at a time when geopolitical tensions, including the war involving Iran, have already pushed energy prices higher.
Pharmaceutical Tariffs Linked to U.S. Manufacturing and Drug Pricing
In a presidential proclamation following a national security review of pharmaceutical imports, the administration outlined new conditions for foreign manufacturers of patented or branded drugs.
Under the policy, pharmaceutical companies must negotiate agreements with the U.S. government to lower prescription drug prices and shift manufacturing operations to the United States. Companies that meet both requirements can avoid tariffs entirely.
However, firms that move only part of their production to the U.S. will face a 20% tariff on their imports. Meanwhile, companies that fail to comply with either requirement could be subject to tariffs as high as 100%.
Trade Agreements Limit Tariffs for Some Countries
Notably, the new tariffs will not apply uniformly to all countries. Under existing trade agreements, tariffs on branded pharmaceutical imports from the European Union, Japan, South Korea, and Switzerland will be capped at 15%.
Additionally, the United States and the United Kingdom have finalized a separate pharmaceutical trade agreement. This deal guarantees zero tariffs on British-made pharmaceuticals for at least three years, while the UK expands its pharmaceutical production capacity in the United States.
Compliance Timeline for Pharmaceutical Companies
As reported by Reuters, the administration has also set specific timelines for compliance. According to officials, large pharmaceutical companies will have 120 days to meet the new requirements before the 100% tariffs take effect.
In contrast, smaller pharmaceutical manufacturers will receive a longer transition period of 180 days to comply with the policy.
Overall, the new tariff strategy reflects the administration’s effort to boost domestic pharmaceutical manufacturing, control drug prices, and reshape global pharmaceutical supply chains.